Protein kinase C epsilon (PKC1) is critical for cardiac protection from ischaemia and reperfusion (IR) injury. PKC1 substrates that mediate cytoprotection reside in the mitochondria. However, the mechanism enabling mitochondrial translocation and import of PKC1 to enable phosphorylation of these substrates is not known. Heat shock protein 90 (HSP90) is a cytoprotective protein chaperone that participates in mitochondrial import of a number of proteins. Here, we investigated the role of HSP90 in mitochondrial import of PKC1.
Introduction
Protein kinase C epsilon (PKC1) activation is required and sufficient to protect the heart from ischaemia and reperfusion (IR) injury. 1 -3 We recently identified mitochondrial aldehyde dehydrogenase 2 (ALDH2) as an intra-mitochondrial substrate of PKC1, 4,5 whose phosphorylation and activation by PKC1 is required to confer cardioprotection. 4 Additional mitochondrial substrates of PKC1 include cytochrome c oxidase subunit IV (COIV), 6 a PKC1 substrate in cardiac myocytes, 6 neuronal cells, 7 and the lens. 8 PKC1 activation also prevents opening of the mitochondrial permeability transition pore (MPTP) 9 and can promote mitochondrial ATP-sensitive K + channel (mitoK ATP ) opening at the inner mitochondrial membrane (IMM), 10 although whether this reflects PKC1-mediated
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A hallmark of PKC activation is translocation of the active enzyme from the cytosol to the cell particulate fraction and a variety of cytoprotective stimuli that activate PKC1, including ischaemic preconditioning, 11 ethanol, 4,5 urocortin, 12 or transgenic expression of constitutively active PKC1, 13 result in elevated mitochondrial levels of PKC1. However, not all studies support a role for mitochondrial PKC1 in cardioprotection. 14, 15 Further, although PKC1 substrates have been shown to reside within mitochondria, the mechanism enabling mitochondrial import of PKC1 has not yet been described. Mitochondrial proteins encoded by nuclear DNA are imported into the mitochondria in a co-translational process, 16 using a 20-50-amino acid residue mitochondrial targeting signal that is recognized by the mitochondrial import receptor, Tom20. PKC1 does not contain a mitochondrial targeting sequence. However, proteins that lack this sequence can be imported into mitochondria in a process mediated by the stress chaperone protein, heat shock protein 90 (HSP90). 17, 18 Here, we examined the role of HSP90 in mediating mitochondrial translocation of PKC1 and its effect on cardiac ischaemia/reperfusion.
Methods

Ex vivo model of cardiac ischaemia -reperfusion
The investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). All protocols were approved by the Stanford University Institutional Animal Care and Use Committee. Hearts from male Wistar rats (275 -300 g) were perfused via the aorta at 10 mL/min with oxygenated Krebs-Henseleit buffer at 378C. Hearts were subjected to 35 min global, no-flow ischaemia followed by 15 min reperfusion. HSP90 inhibitors, geldanamycin (GA; 1 mM) or radicicol (RAD; 1 mM), were perfused during the entire reperfusion period ( Figure 1A) . Cardiac damage was assessed by creatine phosphokinase (CPK) release into the perfusate (Equal Diagnostics, CT, USA). The c1HSP90 peptide (1 mM) was perfused for 10 min prior to ischaemia and during the reperfusion period, in the absence and presence of GA (1 mM; Figure 5A ).
Subcellular fractionation
Heart ventricles were homogenized in ice cold mannitol -sucrose (MS) buffer using a Polytron homogenizer. The heart homogenate was filtered through gauze then centrifuged at 700 g × 5 min. The resultant supernatant was filtered then centrifuged at 10 000 g × 10 min to pellet mitochondria. Mitochondrial pellets were washed three times and resuspended in 200 mL MS buffer. Mitoplasts were generated as described. 19, 20 Mitochondria (50 mL of 10 mg/mL) were resuspended in 450 mL hypotonic buffer (5 mM Tris -HCl and 1 mM EDTA, pH 7.4) and incubated on ice for 15 min before centrifugation at 20 000 g for 10 min at 48C. Mitoplasts were then resuspended in 450 mL hypotonic buffer and sonicated on ice to disrupt the IMM. The solution was then spun at 100 000 g for 40 min with the resultant pellet containing the IMM-enriched fraction and the supernatant containing the matrixenriched fraction. Submitochondrial particles (SMPs) were generated as described. 19, 21 Mitochondria (10 mg/mL in MS buffer) were sonicated 3 × 2 min on ice with 1 min intervals. The solution was spun at 10 000 g for 10 min to pellet unbroken mitochondria and the resultant supernatant spun at 100 000 g for 30 min to pellet SMPs.
Western blotting
Ten micrograms of protein were separated by SDS -PAGE and then transferred to nitrocellulose. Membranes were blocked with 5% milk in Trisbuffered saline (pH 7.5) containing 0.05% Tween (TBS-T), incubated with primary antibody overnight, washed three times in TBS-T, and then incubated with IgG secondary antibody linked to horseradish peroxidase. Protein bands were visualized using chemiluminescence and quantified using ImageJ (NIH).
Immunoprecipitation
Five hundred micrograms of protein were suspended in 1 mL of immunoprecipitation (IP) buffer and incubated with 2 mg PKC1, HSP90, Tom20, or ALDH2 antibodies (Santa Cruz Biotechnology) for 2 h, followed by overnight incubation with Protein A/G beads at 48C. Beads were washed three times in IP buffer and immunoprecipitated proteins detected by western blotting.
Immunogold electron microscopy
Isolated mitochondria were fixed in 4% paraformaldehyde/0.025% gluteraldehyde and 80 nm sections mounted on Ni grids. Mitochondria were incubated with blocking solution, followed by PKC1 antibody (1:100 in blocking solution), followed by goat anti-rabbit IgG conjugated to 10 nm gold particles (Ted Pella Inc.) (1:100 in blocking solution). Mitochondria were imaged using a JEOL 1230 electron microscope. Incubation with secondary antibody (IgG) alone served as controls.
In vitro mitochondrial translocation assay
Isolated mitochondria were incubated with recombinant PKC1 with or without diacylglycerol and phosphatidylserine (DAG/PS; 1 mM; PKC activators), hydrogen peroxide (H 2 O 2; 50 mM), or rabbit reticulocyte lysate (RRL; source of HSP90), and with or without 1 mM c1HSP90. Mitochondrial translocation of recombinant PKC1 was assessed by western blotting.
Sequence alignments
Sequences of the human PKC family members were aligned using ClustalW. Human PKC1 (accession no.: NP_005391.1) was aligned with human HSP90a (accession no.: NP_005339) and HSP90b (accession no.: NP_031381) using L-ALIGN, using the Blosum 80 scoring matrix.
In vivo model of cardiac ischaemiareperfusion
Male Wistar rats (275-300 g) were anaesthetized with isoflurane and myocardial ischaemia was induced by ligation of the left anterior descending (LAD) coronary artery for 35 min, followed by 24 h of reperfusion. Control TAT or c1HSP90 peptides (1 mg/kg in 400 mL saline) were injected intraperitoneally 15 min prior to LAD ligation and 5 min before reperfusion onset. Fractional shortening was determined by echocardiography. Area at risk (AAR) was assessed by re-occlusion of the LAD at the previous suture site, followed by intravenous injection of Evans Blue (1.0 mg/kg). The heart was sectioned into transverse slices, which were incubated with 1% trimethyl tetrazolium chloride (TTC), weighed, and photographed by a digital camera. AAR (negative for Evans Blue) and infarct area (negative for TTC) were quantified using ImageJ and infarct size was calculated as (infarct area/AAR of infarction) × 100 (%).
Statistical analysis
All data are expressed as mean + SEM. Statistical analyses between two groups was performed using the unpaired Student's t-test. Statistical analysis of more than two groups was performed using one-way ANOVA with Dunnett's multiple comparisons post hoc test. A P-value of ,0.05 was considered statistically significant.
Results
HSP90 activity is required for IR-induced mitochondrial translocation of PKC1
Thirty-five-minute global ischaemia followed by 15 min reperfusion induced translocation of PKC1 and PKCd to the mitochondrial fraction ( Figure 1A , B, and D; n ¼ 5; P , 0.05). HSP90 inhibition with GA (1 mM), during reperfusion ( Figure 1A) , attenuated IR-induced mitochondrial translocation of PKC1 by 54% ( Figure 1B and C, left panel, n ¼ 5; P , 0.01), but not mitochondrial translocation of PKCd ( Figure 1B and C, right panel, n ¼ 5). GA had no effect on total PKC1 levels ( Figure 1B) , indicating that reduced mitochondrial PKC1 translocation was not due to increased PKC1 degradation. HSP90 inhibition with RAD (1 mM), which is structurally unrelated to GA, 22 also blocked IR-induced mitochondrial translocation of PKC1 ( Figure 1D ). Mitochondrial purity was confirmed by electron microscopy and western blot analysis with protein markers of cytosolic (GAPDH), plasma membrane (b-integrin), and mitochondrial fractions (mitofusion-1) ( Figure 1E ). GA treatment during reperfusion also increased CPK release by 70% when compared with IR alone ( Figure 1F ; P , 0.05; n ¼ 7), but caused no damage in normoxic perfused hearts, even when used at five-fold higher concentration ( Figure 1F ). HSP90-mediated mitochondrial import of PKC1
Mitochondrial translocation of PKC1 proceeds via the HSP90 -Tom20 import system
Under normoxic conditions, there was no physical association between PKC1 and HSP90 or between PKC1 and Tom20 at the mitochondria ( Figure 2A ). However, PKC1 co-immunoprecipitated with both HSP90 and Tom20 in mitochondria after IR. IR-induced co-IP was observed when immunoblotting the PKC1 immunoprecipitate for the presence of HSP90 or Tom20, and confirmed by the presence of PKC1 in the HSP90 or Tom20 immunoprecipitate. Importantly, IR-induced physical association between PKC1 -HSP90 and PKC1-Tom20 was inhibited by GA, suggesting that HSP90 activity was required. No association between PKC1 and HSP90 was found in the cytosol under any conditions ( Figure 2B ), suggesting that IR-induced PKC1-HSP90 interaction occurs following mitochondrial translocation of PKC1. The IR-induced increase in PKC1 levels was attenuated by GA ( Figure 3A , IR + GA and Figure 3B , n ¼ 3, P , 0.05). There was a complete absence of staining when mitochondria were incubated with anti-rabbit IgG conjugated to immunogold, without prior incubation with the PKC1 antibody (IgG control), excluding non-specific binding due to IgG.
Mitochondrial PKC1 is bound to the IMM
To further investigate the localization of PKC1 in the mitochondria, SMPs were prepared from hearts subjected to IR. SMPs were generated by sonication, creating inside-out mitochondrial vesicles, exposing IMM-associated proteins that face the matrix, and sequestering proteins that face the inner mitochondrial space, like cytochrome c, within the inverted mitochondrial vesicle 21 ( Figure 3C ). Exposure to a 200 mM Na 2 CO 3 carbonate wash at pH 11.5 (which removes strongly bound, but non-integral, membrane proteins) removed PKC1 from the IMM, whereas exposure to 400 mM KCl high-salt wash (which removes loosely associated proteins from membranes) did not dislodge PKC1 from this fraction ( Figure 3D , upper left panel). Trypsin, which cannot cross membranes, completely removed PKC1 from these inside-out mitochondrial vesicles ( Figure 3D , top right panel). That trypsin could access PKC1 suggests that PKC1 is present on the exposed (matrix) side of the IMM in the SMP preparation. 21 In contrast, the levels of cytochrome c, present in the space between the inner and the outer mitochondrial membranes (and therefore resides inside the SMP vesicles), were unaffected by trypsin digestion (Figure 3D, lower right panel) , whereas the adenine nucleotide translocase (ANT), an integral IMM protein, showed a similar sensitivity to trypsin digestion as PKC1 ( Figure 3D , middle right panel).
Mitochondria from hearts exposed to normoxia or IR were also subfractionated to yield IMM-and matrix-enriched components ( Figure 3C , right scheme, and Figure 3E ), which were then probed for PKC1 ( Figure 3E , upper panels). [Purity was confirmed using antibodies against ANT (a marker of IMM), Grp75 (a mitochondrial matrix marker), and enolase (a cytosolic marker).] Similar to the EM analysis, PKC1 in the IMM-enriched fraction increased following exposure to IR and was reduced by GA.
A rationally designed peptide activator of HSP90 and PKC1 interaction (c1HSP90) increases PKC1 translocation to cardiac mitochondria
We previously identified peptide activators of PKC1 that induce protein -protein interaction between PKC1 and its anchoring protein, 1RACK. 3 Specifically, an 8-amino acid peptide corresponding to a sequence in the C2 domain of PKC1 that is homologous to a sequence in 1RACK 3 (hence termed pseudo-1RACK or c1RACK peptide) was found to be an allosteric agonist of PKC1. c1RACK interferes with the auto-inhibitory intra-molecular interaction within PKC1, stabilizing PKC1 in a conformational state in which the 1RACKbinding site on PKC1 is available for inter-molecular interaction with 1RACK. 3, 23 The observation that PKC1 only binds HSP90 upon activation ( Figure 2) , as is the case with PKC1-1RACK binding, led us to reason that the HSP90-binding site on PKC1 may also participate in an auto-inhibitory intra-molecular interaction when PKC1 is inactive. Using L-ALIGN sequence alignment software, we identified (D) SMPs from IR hearts were exposed to 200 mM Na 2 CO 3 (pH 11.5), 400 mM KCl (salt), or trypsin digestion and levels of PKC1, the IMM protein, ANT, and the IMS protein, cytochrome c, were determined by western blotting. (E) IMM and mitochondrial matrix-enriched and cytosolic fractions were probed for PKC1, ANT (a marker of IMM), glucose response protein (Grp75; a marker of matrix fraction), and enolase (a cytosolic marker) from hearts subjected to normoxia, IR, or IR in the presence of 1 mM GA.
HSP90-mediated mitochondrial import of PKC1 PKDNEER at the end of the C2 domain of PKC1 (amino acids 139-145; Figure 4A ) to be homologous to PEDEEEK, found at the end of the middle domain of HSP90 (amino acids 552-558 on HSP90a and 544-550 on HSP90b; Figure 4A ). There are two charge differences between these homologous sequences (Lys 140 and Asn 142 on PKC1 compared with Glu 553 and Glu 555 on HSP90a; red and underlined in Figure 4A ). Such charge differences between the sequences were found in each of the other previous pseudo-site-derived peptides. 24, 25 Further, the HSP90 homologous sequence on PKC1 is not found in any other members of the PKC family ( Figure 4C) , but is evolutionary conserved in PKC1 in a variety of species, including human, rat, mouse, and Xenopus. We synthesized a peptide corresponding to the HSP90 homology region in PKC1 (termed c1HSP90) and conjugated it, via cysteine-cysteine bond, to the cell permeating TAT protein-derived peptide, TAT 47 -57 25 ( Figure 4B) . The effect of c1HSP90 on mitochondrial PKC1 translocation was initially determined, in vitro. Isolated cardiac mitochondria were incubated with recombinant PKC1 in the absence or presence of the PKC activators, DAG/PS (1mM), and/or with hydrogen peroxide (H 2 O 2; 50 mM Figure 4D and E). Unstimulated recombinant PKC1 did not associate with the mitochondria. However, on activation with DAG/PS, there was substantial mitochondrial PKC1 association ( Figure 4D ). H 2 O 2 induced only a limited PKC1 translocation and did not increase the mitochondrial PKC1 translocation induced by DAG/PS ( Figure 4D ). RRL, used as an exogenous source of HSP90, 26 did not increase PKC1 association with the mitochondria, suggesting that HSP90 is already present at the mitochondria. This was also demonstrated by the data in Figure 2A (see also Figure 5D ), in which HSP90 was detected at the mitochondria under normoxic conditions, and in agreement with previous data. 27 In the presence of c1HSP90 peptide (1 mM, Figure 4E) , the H 2 O 2 -induced mitochondrial association of PKC1 was enhanced ( Figure 4E , second to last lane), suggesting that c1HSP90 enhances oxidative stress-induced mitochondrial translocation of PKC1. 
c1HSP90 promotes mitochondrial PKC1 translocation, activates mitochondrial ALDH2, and reduces IR injury
We determined whether c1HSP90 peptide increased mitochondrial translocation of PKC1 in ex vivo hearts. Mitochondria isolated from hearts subjected to IR in the presence of 1 mM c1HSP90 (see protocols in Figure 5A ) had a 35 + 7% increase in PKC1 (n ¼ 5, P , 0.05; Figure 5B and C), when compared with the IR alone group. Mitochondrial PKCd translocation was unaffected by c1HSP90 treatment (Figure 5B and C ) , indicating specificity for PKC1. Further, c1HSP90 did not affect PKC1 translocation to the plasma membrane ( Figure 5B, lower panels) , indicating a selective increase in mitochondrial PKC1. There was no effect of the TAT carrier peptide alone on mitochondrial translocation of PKC1 or CK release (see Supplementary material online, Figure S1 ). Treatment with c1HSP90 also enhanced IR-induced physical interaction between HSP90 and (E) Mitochondrial ALDH2 activity in hearts exposed to IR in the absence and presence of c1HSP90 and GA. (F) Shift of immunoreactive ALDH2 on 2D IEF gels towards acidic pI by c1HSP90 when compared with IR alone, suggesting increased ALDH2 phosphorylation. (G) ALDH2 phosphorylation detected by immunoblotting the ALDH2 immunoprecipitate with anti-phospho Ser/Thr antibody (upper band on blot, distinct from IgG). PKC1 co-IP was also assessed by immunoblotting the ALDH2 immunoprecipitate (middle lane). (H ) CPK release following IR injury, in hearts treated with and without c1HSP90 and GA; mean + SEM (n ¼ 6, *P , 0.05).
HSP90-mediated mitochondrial import of PKC1 PKC1 and the c1HSP90-induced increase in PKC1-HSP90 association was substantially reduced by pharmacological inhibition of HSP90 with GA ( Figure 5D ).
We previously found that selective PKC1 activation results in ALDH2 phosphorylation and increases ALDH2 activity, 4 and that ALDH2 activity correlates with cardioprotection from IR [R 2 ¼ 0.97]. 4 When compared with control-treated hearts, c1HSP90 treatment caused a 38 + 9% increase in ALDH2 activity ( Figure 5E ; n ¼ 6, P , 0.05), an effect that was blocked by HSP90 inhibition with GA ( Figure 5E ; n ¼ 6, P , 0.05). To determine whether increased ALDH2 activity was due to increased ALDH2 phosphorylation, we performed two-dimensional gel immunoelectrophoresis (2D IEF) followed by immunoblotting with anti-ALDH2 antibodies. Similar to our study using c1RACK, 4 immunoreactive ALDH2 shifted to more acidic pI ranges after c1HSP90 treatment when compared with IR alone (Figure 5F ), suggesting increased ALDH2 phosphorylation. This was also confirmed directly by immunoblotting the ALDH2 immunoprecipitate with anti-phospho Ser/Thr antibody ( Figure 5G) . The c1HSP90-induced increase in ALDH2 phosphorylation and activity was prevented by GA, demonstrating the requirement of HSP90. In addition, c1HSP90 treatment increased ALDH2-PKC1 co-IP in these samples ( Figure 5G, lane 3) . Finally, we determined the effect of c1HSP90 peptide on cardiac damage following IR. Hearts treated with c1HSP90 peptide had 50% reduced IR-induced cardiac damage as assessed by CPK release (Figure 5H ; P , 0.05, n ¼ 6), which was attenuated by HSP90 inhibition (Figure 5H ; P , 0.05, n ¼ 5).
c1HSP90 peptide reduces infarct size and increases functional recovery following ischaemia and reperfusion injury, in vivo
We used an in vivo model of acute myocardial infarction in adult male rats that consisted of 35 min ischaemia followed by 24 h reperfusion. Rats were injected intraperitoneally with either c1HSP90 or with the control carrier peptide, TAT, (1 mg/kg in 400 mL saline, each), which were administered 15 min before LAD occlusion and 5 min before the onset of reperfusion ( Figure 6A ). [The dose and route of administration were chosen based on our previous work using other TATconjugated peptides, such as c1RACK and 1V 1 -2 28, 29 .] Treatment with c1HSP90 reduced infarct size by 30% relative to control animals ( Figure 6B ; n ¼ 6, P , 0.05), which had equivalent AAR for infarction ( Figure 6C) . Treatment with c1HSP90 also led to improvement in cardiac function; fractional shortening increased from 31 + 2% in TAT control-treated rats to 40 + 3% in rats treated with c1HSP90 ( Figure 6D ; n ¼ 6, P , 0.05).
Discussion
PKC1 is critical for cardioprotection from IR injury. A number of studies have demonstrated that PKC1-mediated protection is due to phosphorylation of mitochondrial proteins. 4, 6, 8, 13, 30 Here, we report that mitochondrial import of PKC1 is mediated by HSP90 and plays a crucial cardioprotective role. Although previous studies have demonstrated PKC1 activity within mitochondria, 6 -8,10,30 to our knowledge, this study is the first description of interaction between PKC1 and the mitochondrial import machinery and suggests a possible mechanism for mitochondrial translocation of PKC1. We also describe a peptide, designed based on PKC1-HSP90 protein -protein interaction sites (c1HSP90), which increases mitochondrial PKC1-HSP90 interaction, promotes mitochondrial translocation of PKC1, and reduces infarct size ex vivo and in vivo.
A number of cardioprotective stimuli have been found to enhance mitochondrial translocation of PKC, 4, 5, 9, 11, 12, 30 whereas other studies did not support a role for mitochondrial PKC1 in cardioprotection. 14, 15 This discrepancy may be explained by differences in stimulation or models used, the time point at which the translocation analyses were performed, or differences in cellular fractionation techniques. Here, we found that IR-induced mitochondrial translocation of both PKC1 and PKCd when analysed 15 min after reperfusion began. HSP90 inhibition during reperfusion attenuated mitochondrial translocation of PKC1, but not that of PKCd (Figure 1) . Electron microscopy and mitochondrial subfractionation analyses confirmed that intra-mitochondrial PKC1 levels are increased by IR in an HSP90dependent manner and demonstrated that mitochondrial PKC1 is localized at the matrix side of the IMM (Figure 3) . These data are consistent with recent studies reporting PKC1 at the IMM, 10, 30 and with data demonstrating that PKC1 phosphorylates a number of intramitochondrial proteins. 4 -6,8,13,30 Because mitochondrial translocation of PKC1 occurs rapidly, with a corresponding decline in cytosolic PKC1 levels, and since the total cellular PKC1 levels do not change ( Figure 1B) , our data suggest that HSP90 enables dynamic mitochondrial translocation of PKC1 in response to IR. HSP90-mediated mitochondrial import of proteins proceeds via the translocase of the outer membrane (TOM) multiprotein complex through recognition of the chaperoned protein by the import receptors, Tom20, Tom22, or Tom70. 16 We found that IR induced physical association between PKC1 and mitochondrial Tom20, which was prevented by GA. These data suggest that stimulus-induced mitochondrial import of PKC1 proceeds via an HSP90-dependent interaction with the TOM import complex. HSP90 inhibition did not affect IR-induced mitochondrial translocation of PKCd. Other chaperones including HSP70, HSC70, and HSP40 mediate mitochondrial import of proteins; 17, 31 therefore, it is possible that an another chaperone mediates mitochondrial import of PKCd.
HSP90 inhibition with GA during reperfusion resulted in a 70% increase in CK release, indicating that HSP90 mediates a cytoprotective function during reperfusion of ischaemic myocardium. However, HSP90 mediates a number of functions, including mitochondrial translocation of other cytoprotective proteins; 18 therefore, increased damage due to GA was not exclusively due to effects on mitochondrial PKC1. We therefore sought a means to selectively modulate PKC1-HSP90 interaction. Because PKC1 is regulated by multiple intra-molecular interactions, 23, 32 we reasoned that an inhibitory intramolecular interaction may exist between the HSP90-binding site in PKC1 and a sequence within PKC1 that shares homology with a region on HSP90 ( Figure 6E) . The c1HSP90 peptide corresponds to such a 7-amino acid sequence homology between the C2 domain of PKC1, which is homologous with a sequence in the middle domain of HSP90. The C2 domain of PKC1 is known to mediate PKC1 protein-protein interactions, 33 and the corresponding sequence on HSP90 resides within a region that is essential for HSP90 protein -protein interaction. 34 Importantly, charge differences exist between these homologous sequences, characteristic of interaction sites within PKC. 25, 33 Our data demonstrate that c1HSP90 treatment enhanced IR-induced protein-protein interaction between PKC1 and HSP90 ( Figure 5D ), enhanced mitochondrial PKC1 translocation ( Figures 4D and E, and 5B -D), and decreased cardiac injury ( Figures 5H and 6B) . The c1HSP90-induced effects were attenuated by GA, demonstrating that c1HSP90 requires HSP90 ( Figure 5E -H ) . The c1HSP90 peptide did not affect PKCd mitochondrial translocation, demonstrating selectivity for PKC1. Since PKC1 does not associate with HSP90 until activation with IR, it is likely that PKC1-HSP90 interaction is dependent on a conformational change that occurs upon PKC1 activation, which exposes the HSP90-binding site. We propose that c1HSP90 stabilizes the activated PKC1 in a transient conformation that promotes its binding to HSP90, resulting in enhanced mitochondrial import of PKC1 ( Figure 6E) .
We recently identified mitochondrial ALDH2 as a PKC1 substrate, whose activity correlates with cardioprotection from IR. 4 Here, we showed that c1HSP90 increased phosphorylation and activity of ALDH2. Although the current study focused on ALDH2, PKC1 can regulate other mitochondrial functions that mediate cytoprotection, including regulation of mitochondrial respiration and ROS production (mediated by phosphorylation of COIV by PKC1), 6,7,30 regulation of mitochondrial K + flux and mitochondrial matrix swelling, 10 and inhibition of MPTP opening. 9 In summary, our results demonstrate that mitochondrial import of PKC1 is mediated by HSP90 and is required for cardiac protection against IR. Our data suggest a possible mechanism by which PKC1 can access cytoprotective substrates located within the mitochondria to confer cardioprotection. We also describe a novel peptide activator of PKC1, c1HSP90, which promotes mitochondrial PKC1-HSP90 interaction and may have therapeutic use in the treatment of cardiac IR injury. Figure 6 c1HSP90 reduces infarct size and improves functional recovery following ischaemia/reperfusion injury in vivo. (A) An in vivo model of myocardial infarction (B) c1HSP90 reduced infarct size from 57 + 5% in control (TAT carrier treated) to 41 + 6% (n ¼ 6, *P , 0.05). (C) AAR was equal in both experimental groups. (D) c1HSP90 improved fractional shortening from 31 + 2% in controls, to 40 + 3% (n ¼ 6, *P , 0.05). Histograms show mean + SEM (n ¼ 6, *P , 0.05). (E) A proposed scheme of mitochondrial PKC1 translocation. On activation, PKC1 undergoes a conformational change, exposing the HSP90-binding site, enabling HSP90 -PKC1 interaction at the mitochondria and PKC1 interaction with TOM, promoting mitochondrial import of PKC1. The c1HSP90 peptide binds to the open form of PKC1, stabilizing the enzyme in a conformation that promotes PKC1 -HSP90 interaction. Because the affinity of PKC1 for the c1HSP90 peptide is lower than that of the native PKC1-binding site on HSP90, the peptide is displaced when PKC1 binds HSP90 at the mitochondria.
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